BioMarin Pharmaceutical Inc.
HealthcareNASDAQ:BMRN · NASDAQ Global Select
+$0.54 today
Vol 1.07M · Avg 2.06M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$3.2B of revenue converted into $268.7M of net income for the selected period. Gross margin is 76.1% and net margin is 8.4%, showing how much revenue survives after costs and taxes. EPS is $1.39, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2B +12.9% | $2.9B +18.0% | $2.4B +15.4% | $2.1B +13.5% | $1.8B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $736.8M +27.0% | $580.2M +9.1% | $532.1M +5.8% | $503.0M +6.9% | $470.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $2.5B +9.3% | $2.3B +20.5% | $1.9B +18.5% | $1.6B +15.8% | $1.4B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 77.1% -2.5pp | 79.7% +1.7pp | 78.0% +2.0pp | 76.0% +1.5pp | 74.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $921.9M +23.4% | $747.2M +0.1% | $746.8M +15.0% | $649.6M +3.3% | $628.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $1.3B +26.6% | $1.0B +13.1% | $892.4M +8.4% | $823.2M +8.4% | $759.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $2.0B +9.0% | $1.8B +5.2% | $1.7B +18.8% | $1.4B -1.8% | $1.5B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $79.6M -17.5% | $96.4M -7.6% | $104.4M +2.4% | $102.0M -5.6% | $108.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $572.9M -11.9% | $650.5M +112.1% | $306.8M +15.6% | $265.4M +459.4% | $47.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 17.8% -5.0pp | 22.8% +10.1pp | 12.7% +0.0pp | 12.7% +10.1pp | 2.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | $533.5M +10.2% | $484.2M +160.6% | $185.8M +15.4% | $161.0M +295.5% | -$82.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 16.6% -0.4pp | 17.0% +9.3pp | 7.7% -0.0pp | 7.7% +12.1pp | -4.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $74.9M +0.0% | $74.9M +28.4% | $58.3M +223.5% | $18.0M +72.0% | $10.5M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $10.9M -14.0% | $12.7M -26.9% | $17.3M +8.5% | $16.0M +4.1% | $15.3M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$51.0M -188.6% | $57.5M +1963.4% | $2.8M +124.5% | -$11.4M -263.0% | $7.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $482.5M -10.9% | $541.8M +187.3% | $188.6M +26.1% | $149.6M +298.5% | -$75.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 15.0% -4.0pp | 19.0% +11.2pp | 7.8% +0.7pp | 7.1% +11.2pp | -4.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $133.6M +16.3% | $114.9M +449.3% | $20.9M +161.0% | $8.0M +171.1% | -$11.3M | $1.3B | -$1.6B | $745.2M |
| Net Income | $348.9M -18.3% | $426.9M +154.6% | $167.6M +18.4% | $141.6M +320.9% | -$64.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | 10.8% -4.1pp | 15.0% +8.0pp | 6.9% +0.2pp | 6.8% +10.2pp | -3.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 -19.1% | $2 +152.8% | $1 +17.1% | $1 +317.1% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 -18.6% | $2 +151.1% | $1 +17.3% | $1 +314.3% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $191.8M +0.9% | $190.0M +1.2% | $187.8M +1.4% | $185.3M +1.3% | $182.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $197.4M +0.3% | $196.7M +2.7% | $191.6M +1.4% | $189.0M +3.3% | $182.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.74B
Moderna, Inc.
NASDAQ:MRNA
$19.92B
Exelixis, Inc.
NASDAQ:EXEL
$13.37B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.13B
Align Technology, Inc.
NASDAQ:ALGN
$12.51B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.08B
Bio-Techne Corporation
NASDAQ:TECH
$8.46B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.26B
Qiagen N.V.
NYSE:QGEN
$7.66B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$210.23M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BMRN generate?
BioMarin Pharmaceutical Inc. (BMRN) reported $3.22B of revenue in fiscal 2025.
Is BMRN profitable?
BioMarin Pharmaceutical Inc. (BMRN) reported $348.90M of net income, with a net margin of 10.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.